© 2022 MJH Life Sciences and AJMC - Managed Care News, Research, and Expert Insights. All rights reserved.
© 2022 MJH Life Sciences™ and Clinical Care Targeted Communications, LLC. All rights reserved.
Expert panelists provide an overview of the burden of MDS, review currently available treatment options, and explore the clinical and payer considerations of oral treatments.
December 21st 2021
A panel of experts discuss the complex nature of myelodysplastic syndromes and concurrent subclassifications.
January 3rd 2022
Shared insight on how to best educate patients and caregivers on the broad nature of myelodysplastic syndromes.
January 4th 2022
Expert perspectives on the changes in MDS subclassifications as understandings of the disease have evolved.
January 10th 2022
Practical perspectives on how to communicate MDS subclassifications with affected patients and caregivers.
Experts consider shortcomings in the identification and management of myelodysplastic syndromes.
January 17th 2022
Reflections on the historical use of ESAs and blood transfusions to treat patients with myelodysplastic syndromes.
A brief review of disease and patient factors that influence the selection of therapy for myelodysplastic syndromes.
January 24th 2022
Panelists share insight on therapeutic goals when treating patients with myelodysplastic syndromes.
Expert panelists discuss when it’s appropriate to consider or continue ESA therapy or blood transfusions in patients with MDS.
January 31st 2022
Shared insight on the historical and current use of hypomethylating agents in patients with myelodysplastic syndromes.